Latest & greatest articles for geriatrics

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on geriatrics or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on geriatrics and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for geriatrics

61. A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination with Oseltamivir in Elderly and NonElderly Adults Hospitalized with Influenza A Infection: OPAL study Full Text available with Trip Pro

efficacy). Pimodivir is a first-in-class antiviral for influenza A under development for these patients. Methods: Hospitalized patients with influenza A infection were randomized 2:1 to receive pimodivir 600 mg plus oseltamivir 75 mg or placebo plus oseltamivir 75 mg twice daily for 7 days in this phase 2b study. The primary objective was to compare pimodivir pharmacokinetics in elderly (aged 65-85 years) versus non-elderly adults (aged 18-64 years). Secondary endpoints included time-to-patient (...) -reported symptom resolution. Results: Pimodivir pharmacokinetic parameters in non-elderly and elderly patients were similar. Time-to-influenza symptom resolution was numerically shorter with pimodivir (72.45 hours) than placebo (94.15 hours). There was a lower incidence of influenza-related complications in the pimodivir group (7.9%) versus placebo group (15.6%). Treatment was generally well tolerated. Conclusions: No apparent relationship was observed between pimodivir pharmacokinetics and age. Our

2020 EvidenceUpdates

62. Alteplase for Acute Ischemic Stroke in Patients Aged >80 Years: Pooled Analyses of Individual Patient Data Full Text available with Trip Pro

: alteplase; elderly; ischemic stroke; recombinant tissue-type plasminogen activator; thrombolysis. Figures Figure 1. 5 Estimated effect of alteplase vs… Figure 1. 13 Estimated effect of alteplase vs placebo on the odds of good stroke outcome… Figure 1. Estimated effect of alteplase vs placebo on the odds of good stroke outcome by time to treatment, patient age, and stroke severity. A , Time to treatment ( P =0.0203 for interaction). B , Patient age ( P =0.7383 for interaction). C , Stroke severity (...) JA, Lindsberg PJ, Ringleb PA, Wahlgren NG, Lees KR; VISTA Collaborators; SITS Collaborators Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ 2010341c6046.doi: 10.1136/bmj.c6046 - - Show all 33 references Related information LinkOut - more resources Full Text Sources Research Materials Miscellaneous Full-text links [x] [x] Citation text Copy Download .nbib Format: Send To [x] Connect

2020 EvidenceUpdates

63. State handgun purchase age minimums in the US and adolescent suicide rates: regression discontinuity and difference-in-differences analyses. Full Text available with Trip Pro

sales in 2007 and 2008, respectively; and West Virginia and Wyoming, which increased the age for handgun sales in 2010.Adolescents aged 13 to 20 years(554 461 961 from 2001 to 2017) in the regression discontinuity analysis, and adolescents aged 18 to 20 years (168 934 041 from 2002 to 2014) in the main difference-in-differences analysis.Suicide rate per 100 000 adolescents.In the regression discontinuity analysis, state policies that limited the sale of handguns to those aged 18 or older (relative (...) to 21 or older) were associated with an increase in suicide rate among adolescents aged 18 to 20 years equivalent to 344 additional suicides in each state where they were in place between 2001 and 2017. In the difference-in-differences analysis, state policies that limited the sale of handguns to those aged 21 or older were associated with 1.91 fewer suicides per 100 000 adolescents aged 18 to 20 years (95% confidence interval -3.13 to -0.70, permutation adjusted P=0.025). In the difference

2020 BMJ

64. The Contribution of the Age Distribution of Cases to COVID-19 Case Fatality Across Countries: A 9-Country Demographic Study. Full Text available with Trip Pro

diagnosed cases is the same as that among undiagnosed cases and that individuals of all ages are equally susceptible to severe acute respiratory syndrome coronavirus 2 infection.Selective testing and identifying of older cases considerably warps estimates of the lethality of COVID-19 within populations and comparisons across countries. Removing age distortions and focusing on differences in age-adjusted case fatality will be essential for accurately comparing countries' performance in caring (...) The Contribution of the Age Distribution of Cases to COVID-19 Case Fatality Across Countries: A 9-Country Demographic Study. There is wide variation in coronavirus disease 2019 (COVID-19) case-fatality rates (CFRs) across countries, leading to uncertainty about the true lethality of the disease. A large part of this variation may be due to the ages of individuals who are tested and identified.To measure the contribution of distortions from the age distributions of confirmed cases to CFRs within

2020 Annals of Internal Medicine

65. Insufficient evidence for benefits/harms of cognitive impairment screening in asymptomatic older adults. (Abstract)

Insufficient evidence for benefits/harms of cognitive impairment screening in asymptomatic older adults. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for cognitive impairment in older adults: US Preventive Services Task Force recommendation statement. JAMA. 2020;323:757-63. 32096858.

2020 Annals of Internal Medicine

66. Interventions outside the workplace for reducing sedentary behaviour in adults under 60 years of age. (Abstract)

Interventions outside the workplace for reducing sedentary behaviour in adults under 60 years of age. Adults spend a majority of their time outside the workplace being sedentary. Large amounts of sedentary behaviour increase the risk of type 2 diabetes, cardiovascular disease, and both all-cause and cardiovascular disease mortality.Primary • To assess effects on sedentary time of non-occupational interventions for reducing sedentary behaviour in adults under 60 years of age Secondary (...) • To describe other health effects and adverse events or unintended consequences of these interventions • To determine whether specific components of interventions are associated with changes in sedentary behaviour • To identify if there are any differential effects of interventions based on health inequalities (e.g. age, sex, income, employment) SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, Cochrane Database of Systematic Reviews, CINAHL, PsycINFO, SportDiscus, and ClinicalTrials.gov on 14 April

2020 Cochrane

67. Old and New Geriatric Screening Tools in a Belgian Emergency Department: A Diagnostic Accuracy Study

Old and New Geriatric Screening Tools in a Belgian Emergency Department: A Diagnostic Accuracy Study Old and New Geriatric Screening Tools in a Belgian Emergency Department: A Diagnostic Accuracy Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center (...) Copy Actions Cite Share Permalink Copy Page navigation J Am Geriatr Soc Actions . 2020 Jul;68(7):1454-1461. doi: 10.1111/jgs.16503. Epub 2020 May 13. Old and New Geriatric Screening Tools in a Belgian Emergency Department: A Diagnostic Accuracy Study , , , , , , Affiliations Expand Affiliations 1 Department of Public Health and Primary Care, Academic Centre for Nursing and Midwifery, KU Leuven, Leuven, Belgium. 2 Department of Geriatric Medicine, University Hospitals Leuven, Leuven, Belgium. 3

2020 EvidenceUpdates

68. DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Meta-Analysis

study. Am J Med. 2014;127:530-537.e3. Kampfen P, Mean M, Limacher A, et al. Risk of falls and bleeding in elderly patients with acute venous thromboembolism. J Intern Med. 2014;276:378-386. Johnson SA, Eleazer GP, Rondina MT. Pathogenesis, diagnosis, and treatment of venous thromboembolism in older adults. J Am Geriatr Soc. 2016;64:1869-1878. Sterne JA, Bodalia PN, Bryden PA, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease (...) RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Am Geriatr Soc Actions . 2020 May 22. doi: 10.1111/jgs.16549. Online ahead of print. DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Meta-Analysis , , , , , Affiliations Expand Affiliations 1 Division of Hospital Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. 2 Division of Cardiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 3 Evidence-based

2020 EvidenceUpdates

69. Psychotherapy for Depression Across Different Age Groups: A Systematic Review and Meta-analysis

duplicates, 16 756 records were screened and 2608 full-text articles were screened. Of these, 366 trials (36 702 patients) with 453 comparisons between a therapy and a control condition were included in the qualitative analysis, including 13 (3.6%) in children (13 years and younger), 24 (6.6%) in adolescents (≥13 to 18 years), 19 (5.2%) in young adults (≥18 to 24 years), 242 (66.1%) in middle-aged adults (≥24 to 55 years), 58 (15.8%) in older adults (≥55 to 75 years), and 10 (2.7%) in older old adults (...) in middle-aged adults. No significant difference was found between older adults (g = 0.66; 95% CI, 0.51-0.82) and those in older old adults (g = 0.97; 95% CI, 0.42-1.52). The outcomes should be considered with caution because of the suboptimal quality of most of the studies and the high levels of heterogeneity. However, most primary findings proved robust across sensitivity analyses, addressing risk of bias, target populations included, type of therapy, diagnosis of mood disorder, and method of data

2020 EvidenceUpdates

70. Conservative vs Surgical Treatment of Impacted Femoral Neck Fracture in Patients 75 Years and Older

Copy Actions Cite Share Permalink Copy Page navigation J Am Geriatr Soc Actions . 2020 May 15. doi: 10.1111/jgs.16535. Online ahead of print. Conservative vs Surgical Treatment of Impacted Femoral Neck Fracture in Patients 75 Years and Older , , , , , Affiliations Expand Affiliation 1 Department of Orthopaedics, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. PMID: 32413174 DOI: Item in Clipboard Conservative vs Surgical Treatment of Impacted Femoral Neck Fracture in Patients 75 (...) Years and Older Peiran Wei et al. J Am Geriatr Soc . 2020 . Show details J Am Geriatr Soc Actions . 2020 May 15. doi: 10.1111/jgs.16535. Online ahead of print. Authors , , , , , Affiliation 1 Department of Orthopaedics, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. PMID: 32413174 DOI: Item in Clipboard Full-text links Cite Abstract Objective: To evaluate the safety and effectiveness of conservative treatment (CST), internal fixation (IF), and hemiarthroplasty (HA) in treating

2020 EvidenceUpdates

71. Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V

report is the assessment of the added benefit of ivacaftor in combination with tezacaftor/ivacaftor in comparison with the appropriate comparator therapy (ACT) best supportive care (BSC) in patients with cystic fibrosis (CF) aged 12 years and older who are heterozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The patients have one of the following mutations on the second allele: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A?G, S945L, S977F (...) , R1070W, D1152H, 2789+5G?A, 3272-26A?G and 3849+10kbC?T. Table 2: Research questions of the benefit assessment of ivacaftor + tezacaftor/ivacaftor + BSC Therapeutic indication ACT a Patients with cystic fibrosis aged 12 years and older who are heterozygous for the F508del mutation and have one of the following 14 mutations on the second allele in the CFTR gene b : P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A?G, S945L, S977F, R1070W, D1152H, 2789+5G?A, 3272-26A?G and 3849+10kbC?T BSC a: Presentation

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

72. Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V

benefit of ivacaftor in combination with tezacaftor/ivacaftor in comparison with the appropriate comparator therapy (ACT) lumacaftor/ivacaftor in patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Table 2: Research question of the benefit assessment of ivacaftor + tezacaftor/ivacaftor Therapeutic indication ACT a CF patients aged 12 years and older who are homozygous (...) + tezacaftor/ivacaftor) The VX14-661-106 study was a randomized, double-blind, parallel-group study, in which patients were treated with ivacaftor + tezacaftor/ivacaftor or received matching placebo, each against the background of concomitant symptomatic treatment. The study included patients aged 12 years and older who were homozygous for the F508del mutation in the CFTR gene and who had confirmed diagnosis of CF defined as a sweat chloride value of = 60 mmol/L. In addition, the patients had to have

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

73. Ivacaftor (cystic fibrosis, 6 years and older, with G551D mutation) - Addendum to Commission A19-65

]. In its dossier [2], the pharmaceutical company (hereinafter referred to as “the company”) presented results of the randomized controlled trials (RCTs) VX08-770-102 and VX08-770-103 for the assessment of the added benefit of ivacaftor in the treatment of cystic fibrosis in patients aged 6 years and older and weighing 25 kg or more who have the G551D gating mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These studies were included in the benefit assessment (...) , and no information at all on prior and concomitant medication for the relevant subpopulation of the VX08-770-103 study. Hence, the certainty of conclusions of the study results was reduced both for conclusions on patients aged 12 years and older based on the VX08-770-102 study and for children between 6 and 11 years of age based on the VX08-770-103 study. In its comments, the company presented supplementary information on concomitant antibiotic treatment in the studies VX08-770-102 and VX08-770-103, which went

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

74. Ivacaftor (combination with tezacaftor/ivacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Addendum to Commission A19-71

Table 3: Table of the company from the comments: results of the VX14-661-110 study for patients aged 12 years and older who are heterozygous for the F508del mutation in the CFTR gene 9 Addendum A20-06 Version 1.0 Ivacaftor – Addendum to Commission A19-71 30 January 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - v - List of figures Page Figure 1: Treatment sequences of the VX14-661-108 study and analysis groups of the VX14-661-110 extension study 4 Addendum A20-06 Version 1.0 (...) (CF) aged 12 years and older who are heterozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Due to the treatment duration of only 8 weeks, the study was not included in the benefit assessment, but the short-term results were presented as supplementary information. For the outcome “serious adverse events (SAEs)”, the company had presented analyses that included events that can be both symptoms of the underlying disease and side effects

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

75. Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, homozygous) - Addendum to Commission A19-70

with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This adjusted indirect comparison (see Figure 1) was used for the benefit assessment. In its dossier [2], the company had presented analyses for the outcomes “serious adverse events (SAEs)” and “discontinuation due to adverse events (AEs)”. The results of these outcomes contained events that can be both symptoms of the underlying disease (...) (IQWiG) - 2 - 2 Assessment The company had presented analyses on the basis of an indirect comparison (see Figure 1) in its dossier for the assessment of ivacaftor in combination with tezacaftor/ivacaftor in patients with CF aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene. For the outcomes “SAEs” and “discontinuation due to AEs”, the company had shown analyses that contained events that form part of the symptoms of the underlying disease or that can be both side

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

76. Dementia and mild cognitive impairment in prisoners aged over 50 years in England and Wales: a mixed-methods study Full Text available with Trip Pro

Dementia and mild cognitive impairment in prisoners aged over 50 years in England and Wales: a mixed-methods study Dementia and mild cognitive impairment in prisoners aged over 50 years in England and Wales: a mixed-methods study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find (...) the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This study found a relatively high prevalence of dementia/mild cognitive impairment in prisons and it developed a care pathway and training materials for staff and prisoners. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , & . Katrina Forsyth 1 , Leanne Heathcote 1 , Jane Senior 1, * , Baber Malik 1 , Rachel Meacock 1 , Katherine Perryman 1 , Sue Tucker 1 , Rachel

2020 NIHR HTA programme

77. Medication management in older people: the MEMORABLE realist synthesis Full Text available with Trip Pro

Medication management in older people: the MEMORABLE realist synthesis Medication management in older people: the MEMORABLE realist synthesis Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1

2020 NIHR HTA programme

78. Serious harms with long-term PPI use in older adults

groups all agree that they should be prescribed at the lowest dose and for the shortest duration appropriate to the condition treated. However, PPI use continues to expand. Between 2000 and 2018 BC’s population grew by 20%, but use of PPIs increased by 257%. In 2018, 442,559 British Columbians (9% of the population) filled at least one prescription for a PPI. 1 Long-term use of PPIs in older adults We examined use of PPIs from 2008-2018 in people age 65 or older who filled a PPI prescription in BC (...) that net benefits exceed harms during long-term use in older people. Y et despite multiple signals of serious harm, 88% of people over age 65 taking PPIs in BC during 2018 had long-term exposure. Associations detected in observational studies are not proof of causation, but insisting on RCT evidence for fatal and serious adverse events from medication use contravenes modern stan- dards in pharmacovigilance. The standard levels of evidence expected to confirm treatment benefits are not equally appropri

2020 Therapeutics Letter

79. Clinical Study of Spinal Cord Stimulation and Pulsed Radiofrequency for Management of Herpes Zoster-Related Pain Persisting Beyond Acute Phase in Elderly Patients

and need to accept minimally invasive analgesia. Objectives: This study aimed to investigate the effects of spinal cord stimulation (SCS) and pulsed radiofrequency (PRF) on the treatment of elderly patients with HZ-related pain persisting beyond the acute phase. Study design: A prospective, randomized-controlled trial. Setting: Research was conducted at the National Pain Management and Research Center, China-Japan Friendship Hospital (Beijing, China). Methods: We selected 63 patients aged over 50 years (...) Clinical Study of Spinal Cord Stimulation and Pulsed Radiofrequency for Management of Herpes Zoster-Related Pain Persisting Beyond Acute Phase in Elderly Patients Clinical Study of Spinal Cord Stimulation and Pulsed Radiofrequency for Management of Herpes Zoster-Related Pain Persisting Beyond Acute Phase in Elderly Patients - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other

2020 EvidenceUpdates

80. Frailty and associated prognosis among older emergency department patients with suspected infection: A prospective, observational cohort study

of ED presentation (aOR 2.05; 95% CI, 1.02-5.24). Sensitivity for mortality was highest among the CFS (73.1%; 95% CI, 52.2-88.4), compared with SIRS ≥ 2 (65.4%; 95% CI, 44.3-82.8) or qSOFA ≥ 2 (38.4; 95% CI, 20.2-59.4). Conclusions: Frailty is a highly prevalent prognostic factor that can be used to risk-stratify older ED patients with suspected infection. ED clinicians should consider screening for frailty to optimize disposition in this population. Keywords: Frailty; geriatrics; infection; sepsis (...) Frailty and associated prognosis among older emergency department patients with suspected infection: A prospective, observational cohort study Frailty and associated prognosis among older emergency department patients with suspected infection: A prospective, observational cohort study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable

2020 EvidenceUpdates